McKesson (MCK) is back in focus as investors react to upbeat analyst sentiment ahead of its second quarter earnings, with forecasts calling for strong profit growth and closer scrutiny of the company’s guidance.

At a share price of $841.39, McKesson has seen a 12.09% 1 month share price return and a 19.02% 1 year total shareholder return, indicating that recent momentum aligns with longer term compounding.

If the setup around McKesson has you thinking about other opportunities in healthcare, it could be a good time to scan for 39 healthcare AI stocks

McKesson looks like a robust healthcare distributor with solid profit forecasts and upbeat analyst backing, yet the stock’s sharp move to $841.39 raises a sharper question: how much of that strength is already in the price?

Most Popular Narrative: 10.6% Undervalued

McKesson's most followed narrative pegs fair value at $941.40, above the last close of $841.39. This puts the current analyst optimism in a different light.

Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.

Want to see what underpins that fair value gap for McKesson? The narrative leans heavily on revenue expansion, stable margins, and a richer earnings base. Curious which long term assumptions really move the model?

Result: Fair Value of $941.40 (UNDERVALUED)

However, that fair value gap relies heavily on steady margins and policy assumptions, and shifts around drug pricing or biosimilar adoption could quickly challenge the McKesson narrative.

Next Steps

Given the mix of optimism and concern around McKesson, do you want to rely on others, or put the data to work yourself? Check the full balance of potential upsides and the issues investors are watching with 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond McKesson?

If McKesson has sharpened your focus, do not stop there. Use the Simply Wall St screener to surface fresh stock ideas that genuinely fit your approach.

• Target cash generative companies with healthy finances by running the solid balance sheet and fundamentals stocks screener (47 results) so you are not relying solely on headline stories.
• Spot potential mispricings early by scanning the 47 high quality undervalued stocks and compare those candidates with what you are seeing in McKesson today.
• Uncover underfollowed opportunities by tapping into the screener containing 20 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.